Atai Beckley Inc.

NASDAQ:ATAI

Biotechnology

Healthcare
$7.35 -1.35%

-$0.06 today

Market cap
$2.72B
Beta
1.60
P/E (TTM)
-1.4
EPS (TTM)
-$2.93
52W Low $2.00High $6.75

Volume 0.00M

Average 5.68M

ATAI Short-term Investments

Marketable securities and deposits the company expects to convert to cash within a year.

Atai Beckley Inc.NASDAQ: ATAI

Short-term Investments · Q2 FY2026 · quarter ended Jun 2026

Short-term investments rises 67.6% from a year ago

Short-term investments stood at $57M at the end of Q2 FY2026, up 67.6% from a year earlier and down 69.6% from the prior quarter. Over 3 fiscal years it compounded at +27.4% a year.

Context

  • Short-term investments amounted to 21.5% of total assets at the end of Q2 FY2026, up 3.6 pp from a year earlier.
  • Short-term investments increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether short-term investments keeps rising in the next quarterly balance sheet after a +67.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$57M-69.6% QoQ
Last fiscal yearDec 2025
$170.74M+280.9% YoY
Year agoJun 2025
$34M+67.6% since
Short-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+67.6%——
1 year+280.9%——
3-year CAGR+27.4%——
5-year CAGR——
10-year CAGR——

Short-term Investments history

USD · from the balance sheet

Latest · FY2025
170.74M USD
Year-over-year change
+280.9%

Short-term Investments vs competitors

How ATAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +67.6% is the 6th highest of 10, against a peer median of +94.9%.
  • Short-term investments amounts to 21.5% of total assets for ATAI, versus a peer median of 55.3%.
ATAI Competitors
Short-term Investments for ATAI and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RLAYRelay Therapeutics, Inc.Jun 2026$789.75M USD+45.5%-17.8%81.6%
DNTHDianthus Therapeutics, Inc.Jun 2026$776.26M USD+217.9%+80.4%64.0%
ELVNEnliven Therapeutics, Inc.Sep 2026$732.68M USD+94.9%—81.7%
NKTRNektar TherapeuticsJun 2026$645.23M USD+385.4%-17.9%58.9%
AMLXAmylyx Pharmaceuticals, Inc.Sep 2026$528.04M USD+344.4%-31.8%67.1%
ORICORIC Pharmaceuticals, Inc.Mar 2026$225.54M USD+46.1%+19.1%51.6%
SNDXSyndax Pharmaceuticals, Inc.Mar 2026$221.17M USD-39.0%-12.1%46.8%
IMTXImmatics N.V.Mar 2026€152.4M EUR-49.4%-16.7%28.0%
ATAIAtai Beckley Inc.Jun 2026$57M USD+67.6%+27.4%21.5%
SANASana Biotechnology, Inc.Mar 2026$17.34M USD+102.3%-35.4%4.6%
INBXInhibrx Biosciences, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding ATAI) —+94.9%-17.3%55.3%

Competitors are the stored peer set for ATAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents362.27M190.61M45.03M17.51M85.3M
Short-term Investments082.5M134.22M44.83M170.74M
Net Receivables6.32M5.63M2.26M1.35M14.43M
Inventory00000
Other Current Assets756K1.75M846K10.78M946K
Total Current Assets375.08M287.15M185.59M80.13M275.68M
Property, Plant & Equipment (Net)149K1.15M2.2M3.87M4.01M
Goodwill000331K331K
Intangible Assets001.77M3.25M11.59M
Long-term Investments27.76M6.76M91.66M70.97M900K
Tax Assets000017.82M
Other Non-current Assets11.18M10.39M12.25M850K210K
Total Non-current Assets39.08M18.3M107.89M79.26M34.86M
Total Assets414.17M305.44M293.48M159.39M310.54M
Account Payables6M2.4M4.59M2.62M4.91M
Short-term Debt0009.36M271K
Tax Payables8.14M2.22M715K188K0
Deferred Revenue00001.52M
Other Current Liabilities265K718K1.1M2.65M11.11M
Total Current Liabilities20.94M19.9M20.12M24.95M23.48M
Long-term Debt743K15.12M17.88M14.13M0
Deferred Tax Liabilities000017.82M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities6.53M4.62M10.18M3.02M45.44M
Total Non-current Liabilities7.27M19.78M29.04M17.88M65.06M
Total Liabilities28.21M39.68M49.16M42.83M88.54M
Common Stock18M18.56M18.57M18.79M3.63M
Retained Earnings(357.8M)(510.19M)(550.94M)(700.21M)(1.36B)
Accumulated OCI(8.34M)(21.7M)(19.46M)(18.47M)(20.93M)
Other Stockholders Equity0(24K)000
Minority Interest9.05M5.03M1.35M257K127K
Total Equity385.96M265.77M244.32M116.55M222M
Total Debt743K15.34M19.14M24.71M2.07M
Net Debt(361.52M)(175.27M)(25.89M)7.2M(83.23M)

Atai Beckley Inc.

NASDAQ:ATAI

Intrinsic Alpha fair value

Locked

Current Price

$7.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.